Advice

following an abbreviated submission:

budesonide (Cortiment®) is accepted for use within NHSScotland.

Indication under review: Induction of remission in patients with active microscopic colitis.

Cortiment® offers a prolonged release formulation of budesonide for this indication. Other oral budesonide formulations are available at lower cost.

Download detailed advice717KB (PDF)

Download

Medicine details

Medicine name:
budesonide (Cortiment)
SMC ID:
SMC2448
Indication:

Induction of remission in patients with active microscopic colitis (MC)

Pharmaceutical company
Ferring Pharmaceuticals Ltd
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Status
Accepted
Date advice published
17 January 2022